Avancerad sökning

Hittade 3 avhandlingar som matchar ovanstående sökkriterier.

  1. 1. Biomarkers as Monitors of Drug Effect, Diagnostic Tools and Predictors of Deterioration Rate in Alzheimer’s Disease

    Författare :Malin Degerman Gunnarsson; Lena Kilander; Hans Basun; Jan Marcusson; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Alzheimer s disease; biomarkers; CSF; PIB PET; amyloid-beta; tau; rapid cognitive decline; dying in severe dementia; mortality; neuropsychological tests; Medicinsk vetenskap; Medical Science;

    Sammanfattning : Decreased amyloid-ß42 (Aß42), increased total tau (t-tau) and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) reflect histopathological core changes in the most common dementia disorder, Alzheimer’s disease (AD). They discriminate AD from healthy controls and predict conversion to AD with a relatively high accuracy. LÄS MER

  3. 2. Dementia diagnostics in primary care : with a focus on cognitive testing

    Författare :Anna Segernäs Kvitting; Jan Marcusson; Mats Foldevi; Anders Wimo; Hans Basun; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES;

    Sammanfattning : BackgroundAge is the greatest risk factor for developing dementia and the total number of people aged 60 years and above is expected to more than double globally from 2013 to 2050 (1). Primary health care (PHC) is important for basic diagnostic evaluations. LÄS MER

  4. 3. Amyloid β-protein, Cystatin C and Cathepsin B as Biomarkers of Alzheimer's Disease

    Författare :Johan Sundelöf; Lars Lannfelt; Lena Kilander; Hans Basun; Johan Sundstrom; Laura Fratiglioni; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Alzheimer´s disease; amyloid β-protein; cystatin C; cathepsin B; biomarkers; risk factors; epidemiology; Geriatrics and medical gerontology; Geriatrik och medicinsk gerontologi; Medicin; Medicine;

    Sammanfattning : It is suggested that Alzheimer’s disease (AD) is caused by an imbalance between production, degradation and clearance of the amyloid-β (Aβ) protein. This imbalance leads to aggregation of Aβ and tau proteins and neurodegeneration in the brain. LÄS MER